People with kind 2 diabetes (T2D) who had been prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors misplaced considerably extra weight than those that had been prescribed glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), in keeping with the findings of a brand new research led by investigators on the College at Buffalo.
Investigators aimed to judge the variations in weight reduction attributable to GLP-1 RAs and SGLT2 inhibitors, each of that are regularly prescribed for T2D. Amongst 72 sufferers, people receiving SGLT2 inhibitors skilled a median weight lack of greater than 6 lb, in contrast with a median of two.5 lb amongst these receiving GLP-1 RAs.
Canagliflozin was essentially the most generally prescribed SGLT2 inhibitor, and liraglutide was essentially the most generally prescribed GLP-1 RA, in keeping with the research outcomes.
No vital variations had been present in blood stress, blood sugar ranges, or kidney perform after use of the drugs.
The findings counsel that SGLT2 inhibitors could also be extra protecting
in opposition to weight achieve attributable to different antidiabetic medication than GLP-1 RAs, in keeping with a press release.
The findings additionally go in opposition to earlier analysis, which confirmed that GLP-1 RAs are the superior antidiabetic drug for weight reduction, in keeping with the research authors.
They added that though the burden loss attributable to the drug is small, the research outcomes warrant bigger investigations that study the drugs’ affect on weight.
REFERENCE
Antidiabetic drug causes double the burden lack of competitor in kind 2 diabetes sufferers. Information launch. College at Buffalo. July 1, 2021. Accessed July 6, 2021. http://www.buffalo.edu/news/releases/2021/07/001.html
